We examined the ability of two transcutaneous devices (Fastrac, Sensormedics Corporation, Yorba Linda, California, U.S.A. and Hewlett Packard MJ018A, Hewlett Packard Component Monitoring System, Hewlett Packard, North Hollywood, U.S.A.) to measure arterial Peo 2 and P0 2 in neonates. Thirty-seven neonates had transcutaneous oxygen measured with the Hewlett Packard (HP0 2 group), 38 neonates had transcutaneous carbon dioxide measured with the Hewlett Packard (HPe02 group) and the Fastrac was used on 27 neonates (FTe0 2 group). Both devices were operated with electrode temperatures of 43.5°C although an additional ten subjects were studied using the Fastrac with an electrode temperature of 43.0°C. The mean differences (transcutaneous-arterial) and upper and lower limits of agreement were calculated for each group. For the HP0 2 group they were 3.78 mmHg (-12.23 to 19.80 mmHg), for the HPeo 2 group they were 0.40 mmHg and for the FTe02 they were -0.96 mmHg (-7.85 to 5.92 mmHg). For the Fastrac group at an electrode temperature of 43.0°C the mean difference and limits of agreement were -1.00 mmHg and -4.58 mmHg to 2.58 mmHg. The average sensitivity and specificity for both machines for the detection of hypocarbia were 82% and 92% respectively while for hypercarbia they were 90% and 94% respectively. For hypoxaemia, the sensitivity and specijicity were 40% and 94% while for hyperoxaemia the sensitivity and specificity were 83 % and 97%. We conclude that both machines provide a useful supplement to arterial Peo 2 measurements and the Fastrac performs better at 43.0°C. The measurement of p0 2 is less accurate but is still of clinical use.
some circumstances, particularly in neonates, may equal arterial levels.
The purpose of this study was to evaluate the agreement between two transcutaneous devices measuring oxygen and carbon dioxide and arterial blood gases in newborn infants. Despite many studies describing the relationship between transcutaneous and arterial levels!'O, few papers have used the methods of Bland and Altman 2 ! to describe the agreement between transcutaneous and arterial values and have instead simply provided the clinically less useful measures of correlation coefficient. Bland and Altman argue that regression analysis and the correlation coefficient do not provide an appropriate measure of agreement and in fact may be misleading. They suggest instead that one should analyse the difference between the two measurement techniques and calculate the average difference (bias) and the expected range of these differences (limits of agreement). If this is done then large discrepancies between the two techniques can be easily uncovered despite good correlation coefficients. We therefore set out to describe the relationship between the transcutaneous and arterial values for both the Fastrac and Hewlett Packard devices in this manner.
METHODS
We examined the performance of the Fastrac (FT) (Sensormedics Corporation, Yorba Linda, California, U.S.A.) and Hewlett Packard (HP) (M1018A module, Hewlett Packard Component Monitoring System, Hewlett Packard, North Hollywood, U.S.A.) transcutaneous devices on a group of neonates. The FT measures only transcutaneous carbon dioxide while the HP measures both transcutaneous oxygen and carbon dioxide levels. Subjects in this study were neonates admitted to the Neonatal Intensive Care Unit, Royal Children's Hospital, Melbourne, who had an arterial line in situ. Subjects were excluded if they were unstable, known to be septic or had mean arterial blood pressures less than 2.5 standard deviations below agematched controls 22
• 23
• Hospital ethics committee approval was not sought as only arterial blood specimens required for normal clinical care were used and transcutaneous monitoring is a standard, noninvasive part of routine treatment.
Transcutaneous electrodes were heated to 43.5 QC for both calibration and monitoring. This is the highest temperature that the FT can be heated to and was chosen so that oxygen measurements on the HP could be made at the highest possible temperature while also being able to compare the two devices at the same operating temperature.
Various subject demographic data was also recorded including gestation, chronological age, principal diagnosis, weight, the presence of any cardiac condition or use of inotropic support and the mode of ventilation.
Both devices were used in accordance with the manufacturers' instructions. Both transcutaneous devices were calibrated prior to application. Barometric pressure was set to 7fIJ mmHg while the metabolic correction factor was 4 mmHg for both devices. The HP electrode was re-membraned prior to each patient while the Fastrac electrode was re-membraned at least weekly. Electrode placement was timed to coincide with routine arterial blood sampling necessary for clinical care. Both electrodes were placed adjacent to each other on the subject's chest. In a small number of instances the other electrode had to be placed on the subject's abdomen because of space limitations and in a small number of other occasions both electrodes were placed on the infant's back. The devices were positioned relative to the arterial line in order to avoid comparing pre-ductal and post-ductal oxygen measurements. Both electrodes were applied to the patient immediately after calibration. One drop of contact liquid (S44416, Radiometer Copenhagen, Denmark) was applied beneath the FT electrode while approximately four drops were applied beneath the HP electrode. At the time of application patient mean arterial blood pressure (MAP), oxygen saturation (Sa02) and skin temperatures were recorded.
Transcutaneous carbon dioxide readings from the FT (FTC0 2 ) and transcutaneous oxygen and carbon dioxide readings from the HP device (HP0 2 and HPC0 2 ) were obtained at five-minute intervals for 25 minutes after electrode application. After 25 minutes an arterial blood sample was drawn and FTc0 2 , HP0 2 and HPC0 2 readings were recorded. Arterial gases were analysed within five minutes for pH, P0 2 and PC0 2 on an ABL5lO blood gas system (Radiometer-Copenhagen, Copenhagen, Denmark). The standard deviation of this system for repeat measurements performed in quick succession on the same sample is up to 0.5 mmHg for CO 2 and up to 0.6 mmHg for O 2 for all values in the ranges encountered in this study24. FTC02, HP0 2 and HPC0 2 readings were also recorded two minutes after the blood sample was taken to determine whether any delays existed between transcutaneous and arterial measurements if arterial values were changing at the time. MAP, Sa02 and temperature readings were recorded immediately prior to the collection of the arterial blood sample. After data collection the transcutaneous electrodes were removed, dried and exposed to their respective calibration gases in order to evaluate electrode drift. This typically occurred 45 minutes after the first calibration. Data was excluded if the drift was greater than 10070.
Data analysis consisted of the calculation of the mean difference and upper and lower limits of agreement as recommended by Bland and AItman21. The difference between transcutaneous and arterial values was calculated by subtracting the arterial values from the transcutaneous values. Upper and lower limits of agreement were calculated as the mean difference ± 1.96 standard deviations. Ninety-five per cent confidence intervals of the mean difference (bias) were also calculated. Predictive value for the detection of hypoxaemia (arterial or transcutaneous P0 2 < 50 mmHg), hyperoxaemia (arterial or transcutaneous P0 2 > or equal to 90 mmHg), hypocarbia (arterial or transcutaneous PC0 2 < 35 mmHg) and hypercarbia (aterial or transcutaneous PC02 and TC0 2 >or equal to 45 mmHg) were analysed with the calculation of sensitivity, specificity and positive and negative predictive power.
RESULTS
Forty-six neonates admitted to the Neonatal Intensive Care Unit were included in the study. Not all measurements were performed on each subject. Two patients were excluded from the HP0 2 group as group were one day old at the time of testing. One subject from both the HPO z and HPCO z groups had a cardiac condition (transposition of the great arteries) while two subjects in the FTCO z group had cardiac conditions (both transposition of the great arteries). Four subjects in both the HPo z and the HPCO z groups and three subjects in the FTCO z group had patent ductus arteriosus confirmed at the time of testing. Differences between transcutaneous and arterial values in all of the subjects were unremarkable. Ten (27070) HPO z subjects, 10 (26%) HPCOz subjects and 9 (33 %) FTCO z subjects were receiving inotropes (a combination of dopamine, dobutamine or calcium) at the time of testing. Differences between transcutaneous and arterial pco z values were largely unremarkable in these subjects although these subjects accounted for a high proportion of the large transcutaneous overestimations in pO z . Table 3 lists the mean difference (bias), standard deviation (precision), 95% confidence interval for the mean difference and upper and lower limits of agreement between transcutaneous and arterial measurements. Plots of the transcutaneous arterial differences against average values appear in Figures 1,2 and 3 . For the HPO z group the mean difference was 3.78 mmHg with limits of agreement of -12.23 and 19.80 mmHg. For TCOz measurement, the HP and FT devices had similarly small mean differences of 0.40 mmHg and -0.96 mmHg respectively with the FT tending to Table 4 shows the sensitivity, specificity and positive and negative predictive power for the detection of hypoxaemia, hyperoxaemia, hypocarbia and hypercarbia. The FT and HP devices both had good results for the detection of hypocarbia and hypercarbia although the lack of truly hypocarbic subjects in the FT groups limits the value of this data. The average values for sensitivity and specificity obtained from the entire group for the detection of hypocarbia were 82% and 92% while for hypercarbia the average sensitivity and specificity values were 90% and 94% respectively. The sensitivity for hypoxaemia was 40%, possibly low due to the small number of truly hypoxic subjects, with a specificity of 94%, while the sensitivity and specificity for hyperoxaemia were 83% and 97% respectively.
DISCUSSION
Transcutaneous monitors are routinely used in clinical practice to provide a measure of arterial Pe0 2 and P0 2 • Although skin oxygen and carbon dioxide levels do not equal arterial levels under normal conditions, transcutaneous monitors are able to provide a measure of arterial oxygen and carbon dioxide levels by artificially heating the skin surface to temperatures above 37 QC 2S 49. Clinical studies have shown that TC02 is closely related to arterial CO 2 levels in newborn infants under various circumstances'-14 . Unfortunately most published clinical studies have used regression analysis and the calculation of linear correlation coefficients to describe their data with few performing the necessary bias and precision analysis that is required when wanting to determine the ability of one technique to substitute for another 21 . The reported correlation coefficients have been above approximately 0.90 for electrode temperatures above 42 QC even in very ill neonates 2 ,4,9,IO,12,,,. Transcutaneous carbon dioxide typically overestimates arterial pe02 and in studies where the transcutaneous-arterial difference has been examined a mean value of 9 mmHg has been reported '6 while the bias and precision have been reported separately as 5.1 ±7.3 mmHg" and 1.79±4.25 mmHg 2 .
In the current study we found a close relationship between TC02 and peo2 for both the Fastrac and Hewlett Packard devices. The removal of two outliers from the HP02 group and one from the HPeo 2 group, while not having a significant effect on the results, are worth noting for clinical purposes as warning that large discrepancies may sometimes occur despite taking care when using these devices. From our data it appears that the HP more accurately measures pe02 than the FT at 43.5 QC with a mean difference of 0.4 mmHg and limits of agreement of -4.50 mmHg to 5.30 mmHg compared with the mean difference of the FT of -0.96 mmHg with limits of agreement of -7.85 mmHg to 5.92 mmHg. The FT does seem however, and our clinical experience supports this, to perform better at 43.0 QC and this is indicated by the similarly small mean difference and the narrower limits of agreement (-4.58 mmHg to 2.58 mmHg). The mean differences from both machines were small and fell within two standard deviations of the blood gas analyser'S precision, indicating that both machines are able to provide accurate measurements of arterial pe02'
Oxygen measured transcutaneously has typically been less closely associated with arterial levels than is the case for carbon dioxide. In neonates, correlation coefficients ranging from 0.72 to 0.98 have been reported 2 , 8, II, 14, [16] [17] [18] [19] . The mean differences between T0 2 and p0 2 in infants have been reported as 3 mmHg'6 while the bias and precision has been reported as 2.8±16.0 mmHg", 12.5±13.0 mmHg'S and 16.4±24.7 mmHg at p0 2 greater than 80 mmHg and 3.0±1O.2 mmHg at lower P022. The T0 2 /P0 2 ratio is also used and is useful in cases where the bias increases with increasing arterial P0 2 2 and has been reported as being 1.04±0.23 s and 1.05±0.16 at P0 2 less than 80 mmHg and 0.88±0.18 at higher arterial P022. This data shows that although a close relationship between T0 2 and p0 2 is possible, significant disagreement is not uncommon, especially with underestimation of p0 2 at higher levels common 2 ,8,II,IS,IS-20.
Our study found that the Hewlett Packard device provided a better measurement of p0 2 than had been indicated by the published biases and precisions for other devices and provided a relatively good measure of po 2 . As would be expected from the theory of transcutaneous monitoring, T0 2 does not provide a measure of p0 2 as accurately as Te02 does for peo2' The mean difference was 3.78 ± 8.17 mmHg with limits of agreement of -12.23 mmHg to 19.80 mmHg with no apparent tendency for the mean difference to increase with increasing po 2 . Although the limits of agreement are relatively wide, the HP device does provide an approximate guide to arterial p0 2 and more importantly provides the ability to trend p0 2 changes over time in individual patients.
As well as not being as accurate as transcutaneous carbon dioxide readings, the in vivo response of the HP when measuring oxygen was slower than when measuring carbon dioxide. The HPo 2 values were within 10070 of the final values in 75070 of subjects after 15 minutes compared with 10 minutes for the FT and 5 minutes for the HP when measuring CO 2 , Very few published studies have looked at the predictive value of transcutaneous monitors in the detection of hypoxaemia, hyperoxaemia, hypocarbia and hypercarbia. A review by Poets et aPO summarized the findings of nine such studies for hypoxaemia and hyperoxaemia. Hypoxaemia was defined as p0 2 < 50 mmHg and hyperoxaemia was defined Anaesthesia and Intensive Care, Vol, 23, No_ 6, December 1995 as a P0 2 > 80 mmHg. The average sensitivity for hypoxaemia was 85070 while the average specificity was 97%. For hyperoxaemia the average sensitivity was 87% and the average specificity was 89%. One other referenceI 1 reported sensitivities of 83% for hypoxaemia and 75% for hyperoxaemia while another study5l reported sensitivities for hypoxaemia ranging from 89% to 100% and specificities ranging from approximately 50% to 99% for different cut-off levels. Our study found a specificity for hypoxaemia of 83 % which is similar to published studies while the sensitivity was low at 40%. The low number of truly hypoxic patients in this study limits the significance of this sensitivity value however, and the ability to detect hypoxaemia (defined in this study as a P0 2 less than 50 mmHg) in this study is poorer than other published studies as a result. The HP device had good sensitivity and specificity for hyperoxaemia (defined in this study as a P0 2 > or equal to 90 mmHg) and would therefore be useful in its detection. The tendency for the HP to overestimate p0 2 in this study also explains the fact that the device is better at the detection of hyperoxaemia than hypoxaemia.
The sensitivity and specificity for the FT for hypocarbia (defined as a PC0 2 <35 mmHg) was 67% and 88% and for hypercarbia (defined as a PC0 2 > or equal to 45 mmHg) was 88% and 89%. The small number of truly hypocarbic subjects limits the usefulness of the sensitivity data for hypocarbia. The HP had a much better sensitivity for hypocarbia and was slightly better in other respects. For hypocarbia the HP had a sensitivity and specificity of 83% and 97% respectively and for hypercarbia the corresponding values were 91% and 96%. Published reports have reported sensitivities and specificities for hypocarbia as ranging from 45% to 100% and 95% to 99% and for hypercarbia as 74% to 99% and 84% to 88% using similar criteria to those used in this studyB·ll.12.1l. To increase the power of the findings of the current study the results of the two machines were combined. This resulted in average values for the technique itself for sensitivity and specificity for the detection of hypocarbia of 82% and 92% while for hypercarbia the sensitivity and specificity were 90% and 94% respectively. This is similar to published reports and shows that the technique itself is a useful predictor of both hypocarbia and hypercarbia.
This study was able to show that the Hewlett Packard and Fastrac transcutaneous devices both provide an acceptably accurate measure of arterial pC0 2 with the Fastrac performing better at an electrode temperature of 43.0°C than at 43.5°C. The results of this study therefore support the use of both devices in the measurement of PC0 2 • Transcutaneous oxygen was not measured as accurately as carbon dioxide. It does however provide a potentially useful measure of arterial p0 2 in neonates requiring intensive care particularly if individual patient differences are considered and it also provides a useful adjunct to blood gases by providing continuous trend information.
